The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

Infant mortality in the U.S. has increased by 7% since the 2022 Dobbs v. Jackson U.S. Supreme Court decision overturned the ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Kepler Capital analyst Christian Faitz maintained a Hold rating on Bayer (0P6S – Research Report) on January 21 and set a price target of ...

Berenberg Bank analyst Sebastian Bray maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €22.00. The ...

The drug could become the first approved treatment option for women who suffer from hot flashes as they undergo adjuvant endocrine therapy - a treatment for breast cancer. Bayer is facing several ...

The JV will focus on discovering and developing new drugs for conditions including haemophilia, heart disease in infants and a form of blindness called Stargardt. Bayer is just the latest in a ...

Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit ...

Although Bayer’s top-selling drug Xarelto lost market exclusivity in most geographies in 2024, the company still predicts it will see strong growth from the pharma business unit beginning in 2027.

Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group sales, but lower profits for the second quarter. Total revenues ...

That marks a reversal of comments he made at the same meeting a year ago. Bayer now has built the drug pipeline it needs to grow in the next five to seven years, he said. “Acquisitions are ...